Chimerix, Inc.: Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition ...
My 8-year-old’s speech slowed down – 10 months later he was gone
It had just passed midnight on the first day of February half term in 2024. Hours earlier, I had come home from our local ...
Fierce Biotech17h
Chimerix engaged with 7 other biopharmas before choosing Jazz’s $935M deal—here’s why it won
Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...